News from novo nordisk A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 19, 2019, 08:50 ET New "Cities Changing Diabetes" public-private partnership in Philadelphia mobilizing against city's diabetes epidemic

More than 100 health, faith, business and community leaders from across Philadelphia gathered today to learn about emerging research that identify...


Nov 12, 2019, 08:00 ET New Online Reality Series with Actor, Comedian Billy Gardell Chronicles Type 2 Diabetes Transformation Journey

Billy Gardell, star of CBS's hit, new sitcom Bob Hearts Abishola, has teamed up with Novo Nordisk, a company focused on helping people with diabetes, ...


Oct 22, 2019, 09:10 ET FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has expanded the label for Fiasp® (insulin aspart injection) 100 u/mL...


Sep 20, 2019, 10:49 ET FDA approves Rybelsus® (semaglutide), the first GLP-1 analog treatment available in a pill for adults with type 2 diabetes

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus® (semaglutide) tablets 7 mg or 14 mg for adults...


Sep 10, 2019, 10:03 ET New global survey highlights impact of diabetes management on family members

According to a new international survey of 4,300 family members of people living with type 1 and type 2 diabetes, many report worrying about their...


Aug 14, 2019, 13:00 ET Calling life science innovators: don't miss your chance for a "Golden Ticket" to LabCentral

Wanted: high-potential life sciences and biotech start-up companies looking for an opportunity to be part of a vibrant innovation ecosystem where...


Jun 17, 2019, 17:41 ET FDA approves Victoza® for the treatment of type 2 diabetes in children and adolescents aged 10-17 years

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Victoza® (liraglutide)...


Jun 11, 2019, 14:45 ET Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

Novo Nordisk today announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular...


Jun 08, 2019, 11:45 ET Oral semaglutide showed superior reductions in blood sugar vs Jardiance® and non-inferior blood sugar reductions vs Victoza® in adults with type 2 diabetes at 26 weeks

Findings presented today from two phase 3a clinical trials evaluated oral semaglutide 14 mg vs Jardiance® (empagliflozin 25 mg) in PIONEER 2 and oral ...


May 22, 2019, 10:43 ET Novo Nordisk to present data on oral semaglutide at the 79th Annual American Diabetes Association Scientific Sessions

Novo Nordisk today announced that new data from its diabetes portfolio will be presented at the upcoming 79th Annual Scientific Sessions of the...


Apr 30, 2019, 12:15 ET Renewable electricity to completely power Novo Nordisk US operations in early 2020

Beginning in early 2020, Novo Nordisk's global production will be completely powered by renewable electricity, with a ten-year goal of achieving zero ...


Apr 28, 2019, 18:00 ET Victoza® demonstrated superiority in reducing blood sugar vs placebo in children and adolescents with type 2 diabetes

Novo Nordisk today announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza®...


Mar 23, 2019, 14:00 ET Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Oral semaglutide 7 mg and 14 mg demonstrated superior A1C and body weight reductions compared to Januvia® (sitagliptin 100 mg). Non-inferiority for...


Mar 20, 2019, 10:08 ET Novo Nordisk files for US FDA approval of oral semaglutide for blood sugar control and cardiovascular risk reduction in adults with type 2 diabetes

Novo Nordisk today announced the submission of two New Drug Applications (NDAs) to the US Food and Drug Administration (FDA) for oral semaglutide,...


Mar 04, 2019, 08:03 ET Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors

Novo Nordisk today announced publication of results from the SUSTAIN 9 Phase 3b trial in The Lancet Diabetes & Endocrinology. The objective of this...


Mar 01, 2019, 07:00 ET Novo Nordisk files for a label update for Fiasp® to the EMA and the FDA seeking approval for use in children and adolescents

Novo Nordisk today announced that it recently submitted label updates to the European Medicines Agency (EMA) and the US Food and Drug Administration...


Oct 22, 2018, 12:46 ET Cardiovascular safety data added to Saxenda® label

Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) approved an updated label for Saxenda® (liraglutide) injection 3 mg....


Jun 23, 2018, 10:12 ET Tresiba® demonstrated significantly lower A1C and rates of hypoglycaemia versus insulin glargine U-300 in real-world evidence study

Findings from CONFIRM – a large, retrospective real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection)...


Jun 23, 2018, 10:09 ET Ozempic® provided greater weight reductions for adults with a baseline BMI ≥25kg/m2 than those with lower baseline BMI <25kg/m2, in a SUSTAIN 7 post-hoc analysis

Ozempic® (semaglutide) injection 0.5 mg or 1 mg provided greater weight reductions vs dulaglutide 0.75 mg or 1.5 mg, respectively, in adults with...


Jun 23, 2018, 10:06 ET Oral semaglutide demonstrated significant reduction in blood sugar vs placebo in PIONEER 1 trial

Oral semaglutide, an investigational GLP-1 receptor agonist taken as a once-daily tablet, achieved significant reductions in blood sugar versus...


Jun 23, 2018, 08:05 ET Significant blood sugar improvement with Xultophy® 100/3.6 compared to insulin glargine U-100 when used as add-on to oral diabetes medications

Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin...


Jun 18, 2018, 10:32 ET Novo Nordisk to present 39 abstracts at the 78th Annual American Diabetes Association Scientific Sessions

Novo Nordisk today announced that the company will share data from 39 abstracts discussing a breadth of new clinical, real-world and patient...


May 21, 2018, 04:00 ET Head-to-head pharmacokinetic study demonstrated greater factor IX activity with Rebinyn® versus rFIXFc in people with hemophilia B

A new head-to-head pharmacokinetic study showed that adults with hemophilia B who received a single dose (50 IU/kg) of Rebinyn® [Coagulation Factor...


May 10, 2018, 09:30 ET INDYCAR Driver Charlie Kimball and Novo Nordisk unveil new No. 23 Fiasp® Chevrolet® for 2 races in Indianapolis during the month of May

Charlie Kimball, driver of the No. 23 Chevrolet® for Carlin, will carry new colors for the month of May as Novo Nordisk, a world leader in diabetes...


Mar 26, 2018, 09:56 ET FDA approves inclusion of data from safety outcomes trial in the Tresiba® label

Novo Nordisk today announced that the US Food and Drug Administration (FDA) approved updates to the prescribing information (PI) for Tresiba®...